247
Views
8
CrossRef citations to date
0
Altmetric
Research Articles

Computational screening and MM/GBSA-based MD simulation studies reveal the high binding potential of FDA-approved drugs against Cutibacterium acnes sialidase

ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 6245-6255 | Received 21 Mar 2023, Accepted 29 Jun 2023, Published online: 07 Aug 2023
 

Abstract

Cutibacterium acnes is an opportunistic pathogen linked with acne vulgaris, affecting 80–90% of teenagers globally. On the leukocyte (WBCs) cell surface, the cell wall anchored sialidase in C. acnes virulence factor, catalysing the sialoconjugates into sialic acids and nutrients for C. acnes resulting in human skin inflammation. The clinical use of antibiotics for acne treatments has severe adverse effects, including microbial dysbiosis and resistance. Therefore, identifying inhibitors for primary virulence factors (Sialidase) was done using molecular docking of 1030 FDA-approved drugs. Initially, based on binding energies (ΔG), Naloxone (ZINC000000389747), Fenoldopam (ZINC000022116608), Labetalol (ZINC000000403010) and Thalitone (ZINC000000057255) were identified that showed high binding energies as −10.2, −10.1, −9.9 and −9.8 kcal/mol, respectively. In 2D analysis, these drugs also showed considerable structural conformer of hydrogen and hydrophobic interactions. Further, a 100 ns MD simulation study found the lowest deviation and fluctuations with various intermolecular interactions to stabilise the complexes. Out of 4, the Naloxone molecule showed robust, steady, and stable RMSD 0.23 ± 0.18 nm. Further, MMGBSA analysis supports MD results and found strong binding energy (ΔG) −29.71 ± 4.97 kcal/mol. In Comparative studies with Neu5Ac2en (native substrate) revealed naloxone has a higher affinity for sialidase. The PCA analysis showed that Naloxone and Thalitone were actively located on the active site, and other compounds were flickered. Our extensive computational and statistical report demonstrates that these FDA drugs can be validated as potential sialidase inhibitors.

Communicated by Ramaswamy H. Sarma

Acknowledgements

The author is greatly acknowledged and thankful to the director of CSIR-IGIB for providing the research facility and carrying out research work and Jamia Millia Islamia for providing computational and other support for smooth work.

Availability of data and material

All the data in supplementary material provided for extended validation or analysis produced during the docking phase can be made public after publication.

Authors’ contributions

Conceptualisation, data collection/curation, analysis, writing, reviewing the first draft: Akash Pratap Singh. Conceptualisation, data collection/curation, analysis, writing, reviewing and editing the first draft: Shaban Ahmad. Computational resources, reviewing, editing the first draft: Hemant K. Gautam. Computational resources, reviewing and editing: Khalid Raza.

Consent for publication

All authors consent to submit the manuscript to the journal.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Ethical responsibilities

This study does not directly involve humans or other organisms.

Additional information

Funding

The author (APS) received a Senior Research Fellowship (31/0430410)/2019-EMR-I) from the Council of Scientific & Industrial Research (CSIR), India.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.